You just read:

Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer

News provided by

Janssen Biotech, Inc.

Oct 11, 2017, 08:44 ET